A Phase 1/2 interventional study of ICP-022 and ICP-022 in Systemic Lupus Erythematosus, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 89th largest by enrollment of the 245 interventional ones that give a count, is one of 7 that started in 2020, is one of 19 in phase 1/2, and was the 41st registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in China, Australia, Brazil and 3 more countries
Ages 18–75
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
Peking Union Medical College Hospital · Sites in China
Ages 6–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 128 · Phase 2 56 · Phase 3 36 · Phase 4 16
First in 2006; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 36 across the 245 interventional studies, 180 across the 21 observational. Of the 54 that completed or were terminated, 25 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 266 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 3 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
58 of the studies in Lupus Erythematosus, Systemic with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07657793Phase 3Chinese SLE Treatment And Research GroupSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | 2027-09-30 |
Add all 58 to your calendar (.ics) → With an account.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ICP-022
Drug: ICP-022
Drug: ICP-022
Drug: Placebos
Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Also known as: Orelabrutinib
Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Also known as: Orelabrutinib
Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Also known as: Orelabrutinib
Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to 28 Days after the last dose of study drug
Number of Patients with Treatment-emergent Adverse Event(TEAEs) according to severity
Time frame: Up to 28 Days after the last dose of study drug
Number of participants with clinically significant physical examination abnormalities
Time frame: Up to 28 Days after the last dose of study drug
Number of participants with clinically significant vital signs abnormalities
Time frame: Up to 28 Days after the last dose of study drug
Number of participants with clinically significant ECG abnormalities
Time frame: Up to 28 Days after the last dose of study drug
Number of participants with clinically significant laboratory examination abnormalities
Time frame: Up to 28 Days after the last dose of study drug
Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4)
Time frame: 12 Weeks
Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6)
Time frame: 12 Weeks
Occupancy rate of Bruton Tyrosine Kinase(BTK)
Time frame: 14 Days
Serum Immunoglobulin (Ig) level
Time frame: 12 Weeks
Changes from Baseline in Ig levels
Time frame: 12 Weeks
Changes from Baseline in C3
Time frame: 12 Weeks
Changes from Baseline in C4
Time frame: 12 Weeks
Changes from Baseline in serum dsDNA
Time frame: 12 Weeks
Changes from Baseline in Anti-nuclear Antibodies
Time frame: 12 Weeks
Changes from Baseline in Interferon-α(INF-α) level
Changes from Baseline in cytokine levels
Time frame: 12 Weeks
Changes from Baseline in Interleukin-6(IL-6) level
Changes from Baseline in cytokine levels
Time frame: 12 Weeks
Changes from Baseline in total B cell counts
Time frame: 12 Weeks
Change from Baseline in Beffs count
Time frame: 12 Weeks
Changes from baseline in Bregs count
Time frame: 12 Weeks
Changes from Baseline in Bregs to Beffs ratio
Time frame: 12 Weeks
Changes from Baseline in Erythrocyte Sedimentation Rate(ESR)
Time frame: 12 Weeks
The plasma concentration-time curve
Time frame: 14 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Apr 2022, 21 months.
Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orelabrutinib
Lupus Erythematosus, Systemic →
Beijing InnoCare Pharma Tech Co., Ltd. →